Drug Trial Radar · NCT05110976
A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists
Last checked: Nov 19, 2026Latest source record: Aug 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
170
Actual
Start
Dec 16, 2021
Primary completion
Aug 2, 2023
Study completion Aug 2, 2023
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a first in human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8630 in healthy adults (Part A) and adult asthma patients on medium to high dose inhaled corticosteroids / Long-acting beta-agonists (Part B)
Conditions
- Asthma
Interventions
AZD8630Drug
Participants will receive Inhaled or IV doses of AZD8630 as per the arm they are assigned.
PlaceboDrug
Participants will receive Inhaled or IV doses of placebo as per the arm they are assigned.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A and Part B: Number of participants with adverse eventsTime frame: Until Follow-up (FU) Visit/Early Termination (ET) Visit (Part A: 7-day post-dose for SAD; 10-day post-last dose for MAD) and Part B: Until FU Visit/ET Visit (10-day post-last dose)
- Part A (IV cohort): Time to reach maximum observed concentration (tmax) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
- Part A (IV cohort): Time of last observed quantifiable concentration (tlast) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
- Part A (IV cohort): Maximum observed serum (peak) drug concentration (Cmax) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
- Part A (IV cohort): Partial area under the serum concentration-time curve from 0 to time 24 hours post-dose [AUC(0-24)] of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
- Part A (IV cohort): Area under the serum concentration curve from zero to the last quantifiable concentration (AUClast) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
- Part A (IV cohort): Area under serum concentration-time curve from zero to infinity (AUCinf) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
- Part A (IV cohort): Terminal rate constant (λz) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
- Part A (IV cohort): Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
- Part A (IV cohort): Mean residence time of the unchanged drug in the systemic circulation (MRTinf) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
- Part A (IV cohort): Total body clearance of drug from serum after IV administration (CL) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
- Part A (IV cohort): Volume of distribution at steady state (Vss) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
- Part A (IV Cohort): Volume of distribution of drug from serum after IV administration (Vz) of AZD8630Time frame: Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
- Part A (IV Cohort): Number of participants with adverse eventsTime frame: Until Follow-up (FU) Visit/Early Termination (ET) Visit (7-day post-dose)
Locations
29 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
Tempe, Arizona
Research Site
Bakersfield, California
Research Site
Glendale, California
Research Site
San Jose, California
Research Site
Homestead, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Boise, Idaho
Research Site
White Marsh, Maryland
Research Site
North Dartmouth, Massachusetts
Research Site
Ann Arbor, Michigan
Research Site
Raleigh, North Carolina
Research Site
Toledo, Ohio
Research Site
Portland, Oregon
Research Site
El Paso, Texas
Research Site
Berlin, Germany
Research Site
Frankfurt, Germany
Research Site
Großhansdorf, Germany
Research Site
Lübeck, Germany
Research Site
Magdeburg, Germany
Research Site
Wiesbaden, Germany
Research Site
Bradford, United Kingdom
Research Site
London, United Kingdom
Research Site
London, United Kingdom
Research Site
Manchester, United Kingdom
Research Site
Portsmouth, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.